September 15, 2026 05:00 ET | Source: Hummingbird Bioscience SINGAPORE, Sept. 15, 2026 (GLOBE NEWSWIRE) — Hummingbird Bioscience (“Hummingbird”), a biotherapeutics company discovering and developing transformative medicines for diseases with significant unmet need, today announced the appointment of Dr. James Garner as President. Dr. Garner will join Hummingbird Bioscience’s leadership team and work alongside Piers Ingram, PhD, […]
BEXLUTRY is the first radioligand equivalent for the treatment of GEP-NETs in adults and the first radioligand therapy from Curium™ approved by the FDA September 14, 2026 17:49 ET | Source: Curium BOSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) — Curium™ announced today that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA)
September 14, 2026 08:03 ET | Source: Teva Pharmaceutical Industries Ltd PARSIPPANY, N.J. and TEL AVIV, Israel, Sept. 14, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), a global biopharmaceutical company, today announced that its ordinary shares will begin trading today directly on the New York Stock Exchange (NYSE) completing the company’s planned
September 10, 2026 20:00 ET | Source: Avance Clinical TAIPEI, Taiwan, Sept. 10, 2026 (GLOBE NEWSWIRE) — Avance Clinical Taiwan has won the Australia-Taiwan Business Excellence Award at the 2026 Australia New Zealand Chamber of Commerce in Taiwan (ANZCham Taiwan) Business Awards, held at Shangri-La’s Far Eastern Plaza Hotel in Taipei. The award is one of only
September 10, 2026 08:00 ET | Source: Adagene Inc. Amended terms of agreement include a transition to an integrated asset and technology partnership. SAN DIEGO and SUZHOU, China, Sept. 10, 2026 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies today announced that Third
September 10, 2026 06:04 ET | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, Sept. 10, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it successfully priced its offering of approximately $4.9 billion (equivalent) of senior notes (the “Notes”). Teva expects to use the net proceeds from the offering,
Regulatory milestone strengthens Australia’s sovereign advanced therapeutics manufacturing capability September 10, 2026 01:08 ET | Source: VIRAL VECTOR MANUFACTURING FACILITY PTY. LTD. SYDNEY, Sept. 10, 2026 (GLOBE NEWSWIRE) — Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s first viral vector Contract Development and Manufacturing Organisation (CDMO) advises that the Therapeutic Goods Administration (TGA) has granted the company
September 09, 2026 14:01 ET | Source: Dark Horse Consulting Group WALNUT CREEK, Calif. and SHANGHAI, Sept. 09, 2026 (GLOBE NEWSWIRE) — Dark Horse Consulting Group (DHCG) marked the opening of its Shanghai office with a ribbon cutting ceremony celebrating Dark Horse Consulting China. The event brought together DHCG leadership, “Shanghai Center of Biomedicine Development”, “China leading
September 09, 2026 08:00 ET | Source: Callio Therapeutics Veteran biotech executive to lead company growth as it advances multiple dual-payload ADCs through clinical development for people living with cancer Piers Ingram, PhD, Co-Founder, transitions to Senior Advisor and continues to serve on the Board of Directors; Jerome Boyd-Kirkup, PhD, founding Chief Scientific Officer, transitions to Senior
September 09, 2026 08:00 ET | Source: Adagene Inc. SAN DIEGO and SUZHOU, China, Sept. 09, 2026 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced the achievement of a milestone in its ongoing collaboration and license agreement with Exelixis, Inc. (“Exelixis”).
Strategic investment will support continued advancement of the Accumulus platform and expand global adoption across the life sciences regulatory ecosystem September 09, 2026 07:00 ET | Source: Accumulus Technologies SAN FRANCISCO, Sept. 09, 2026 (GLOBE NEWSWIRE) — Accumulus Technologies today announced that it has been acquired by Eir Partners, an investment firm specializing in healthcare technology and
September 09, 2026 04:30 ET | Source: PetSuper Smart Technology Co.,Ltd BERLIN, Sept. 09, 2026 (GLOBE NEWSWIRE) — PetSuper, a smart pet technology brand focused on developing intelligent products that enhance everyday pet care, made its debut at IFA 2026. Showcasing its connected smart pet portfolio and its evolving vision for an AI-powered smart pet ecosystem, the brand
September 07, 2026 03:53 ET | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, Sept. 07, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today its intention to issue senior notes through its special purpose finance subsidiaries. Teva Pharmaceutical Finance Netherlands II B.V. (“Teva Finance II”) intends to offer EUR-denominated Senior
September 04, 2026 11:30 ET | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, Sept. 04, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that S&P Global Ratings (“S&P”) has upgraded Teva’s long-term issuer credit rating to BBB- from BB+, with a Stable outlook. With this upgrade, along with the other
September 03, 2026 12:00 ET | Source: Curia Global, Inc. ALBANY, N.Y., Sept. 03, 2026 (GLOBE NEWSWIRE) — Curia Global, Inc. (Curia), a leading global research, development and manufacturing organization, today announced the grand opening of its expanded campus in Albuquerque, New Mexico. Company leaders hosted federal, state and local officials at a ribbon-cutting ceremony, including John
